Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma

Sendur M. A. N., AKSOY S., Ozdemir N. Y., Zengin N.

INDIAN JOURNAL OF PHARMACOLOGY, cilt.46, sa.1, ss.125-126, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 46 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.4103/0253-7613.125195
  • Dergi Adı: INDIAN JOURNAL OF PHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.125-126
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.